254 related articles for article (PubMed ID: 36039643)
1. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
2. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
3. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic metabolic genes in adrenocortical carcinoma and establishment of a prognostic nomogram: A bioinformatic study.
Chen Q; Ren Z; Liu D; Jin Z; Wang X; Zhang R; Liu Q; Cheng W
Medicine (Baltimore); 2021 Dec; 100(50):e27864. PubMed ID: 34918636
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
8. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
9. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
Surgery; 2022 Jan; 171(1):111-118. PubMed ID: 34261605
[TBL] [Abstract][Full Text] [Related]
10. Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering.
Zhang Y; Zhang C; Li K; Deng J; Liu H; Lai G; Xie B; Zhong X
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895143
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma.
Zhu B; Zhi Q; Xie Q; Wu X; Gao Y; Chen X; Shi L
J Trace Elem Med Biol; 2019 Dec; 56():52-59. PubMed ID: 31442954
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma.
Wu K; Liu Z; Liang J; Zhu Y; Wang X; Li X
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793855
[TBL] [Abstract][Full Text] [Related]
13. High expression of GMNN predicts malignant progression and poor prognosis in ACC.
Zhao X; Zhang X; Shao S; Yang Q; Shen C; Yang X; Jiao W; Liu J; Wang Y
Eur J Med Res; 2022 Dec; 27(1):301. PubMed ID: 36539849
[TBL] [Abstract][Full Text] [Related]
14. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
J Cell Mol Med; 2021 Nov; 25(21):10061-10072. PubMed ID: 34664400
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
16. Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
Yang Z; Cheng H; Zhang Y; Zhou Y
Med Sci Monit; 2021 Mar; 27():e928523. PubMed ID: 33667214
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data.
Tian X; Xu W; Wang Y; Anwaier A; Wang H; Wan F; Zhu Y; Cao D; Shi G; Zhu Y; Qu Y; Zhang H; Ye D
Oncoimmunology; 2020 Jun; 9(1):1784529. PubMed ID: 32923148
[TBL] [Abstract][Full Text] [Related]
18. Screening and identification of immune-related genes for immunotherapy and prognostic assessment in colorectal cancer patients.
Wang S; Cheng L; Jing F; Li G
BMC Med Genomics; 2022 Aug; 15(1):177. PubMed ID: 35941638
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract][Full Text] [Related]
20. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]